Review article: epoxyeicosatrienoic acids: novel mediators of cardioprotection
- PMID: 20200327
- DOI: 10.1177/1074248409358408
Review article: epoxyeicosatrienoic acids: novel mediators of cardioprotection
Abstract
Recent evidence from a number of in vitro and in vivo studies in isolated cells and animal models has suggested that the cytochrome P450 (CYP450) pathway of arachidonic acid (AA) metabolism produces potent cardioprotective metabolites that markedly reduce reversible (myocardial stunning) and irreversible (infarct size [IS]) injury in the ischemic/reperfused heart. The major players in this protective response appear to be the AA metabolites including the regioisomers of 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs). The present review article will discuss the beneficial effects of the EETs on myocardial stunning and IS reduction and consider some of the signaling pathways and cellular mechanisms by which the EETs produce their beneficial effects and the possible therapeutic benefits that may result from activation of this pathway. The results discussed in this review are taken from experiments obtained from 3 diverse species in different laboratories: the mouse, rat, and dog, in which the results were nearly identical qualitatively and quantitatively, suggesting that these findings are likely to be extrapolated to man as well.
Similar articles
-
Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited.Cardiovasc Res. 2005 Oct 1;68(1):18-25. doi: 10.1016/j.cardiores.2005.06.007. Cardiovasc Res. 2005. PMID: 15993870
-
[Cytochrome P450/epoxyeicosatrienoic acids system and myocardial ischemic-reperfusion injury].Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005 Aug;27(4):539-42. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005. PMID: 16178456 Review. Chinese.
-
Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs.Anal Biochem. 2001 May 1;292(1):115-24. doi: 10.1006/abio.2001.5044. Anal Biochem. 2001. PMID: 11319825
-
Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway.Circ Res. 2004 Oct 15;95(8):e65-71. doi: 10.1161/01.RES.0000146277.62128.6f. Epub 2004 Sep 23. Circ Res. 2004. PMID: 15388642
-
Signalling pathways in ischaemic postconditioning.Thromb Haemost. 2009 Apr;101(4):626-34. Thromb Haemost. 2009. PMID: 19350104 Review.
Cited by
-
Epoxides and soluble epoxide hydrolase in cardiovascular physiology.Physiol Rev. 2012 Jan;92(1):101-30. doi: 10.1152/physrev.00021.2011. Physiol Rev. 2012. PMID: 22298653 Free PMC article. Review.
-
Influence of silencing soluble epoxide hydrolase with RNA interference on cardiomyocytes apoptosis induced by doxorubicin.J Huazhong Univ Sci Technolog Med Sci. 2011 Jun;31(3):324. doi: 10.1007/s11596-011-0375-6. Epub 2011 Jun 14. J Huazhong Univ Sci Technolog Med Sci. 2011. PMID: 21671172
-
Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension.Clin Sci (Lond). 2012 Jun;122(11):513-25. doi: 10.1042/CS20110622. Clin Sci (Lond). 2012. PMID: 22324471 Free PMC article.
-
Soluble Epoxide Hydrolase Inhibitors Regulate Ischemic Arrhythmia by Targeting MicroRNA-1.Front Physiol. 2021 Sep 27;12:717119. doi: 10.3389/fphys.2021.717119. eCollection 2021. Front Physiol. 2021. PMID: 34646152 Free PMC article.
-
Epoxide hydrolase 1 (EPHX1) hydrolyzes epoxyeicosanoids and impairs cardiac recovery after ischemia.J Biol Chem. 2018 Mar 2;293(9):3281-3292. doi: 10.1074/jbc.RA117.000298. Epub 2018 Jan 3. J Biol Chem. 2018. PMID: 29298899 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical